Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Importance of pharmacokinetics in the management of hemophilia.

Barnes C.

Pediatr Blood Cancer. 2013;60 Suppl 1:S27-9. doi: 10.1002/pbc.24339. Epub 2012 Oct 25. Review.

PMID:
23109436
2.
3.

Hemophilia and prophylaxis.

Ljung R.

Pediatr Blood Cancer. 2013;60 Suppl 1:S23-6. doi: 10.1002/pbc.24340. Epub 2012 Oct 25. Review.

PMID:
23109472
4.
5.

Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.

Mahdi AJ, Obaji SG, Collins PW.

Br J Haematol. 2015 Jun;169(6):768-76. doi: 10.1111/bjh.13360. Epub 2015 Mar 7. Review.

PMID:
25754016
6.

The pharmacokinetics of clotting factor therapy.

Berntorp E, Björkman S.

Haemophilia. 2003 Jul;9(4):353-9. Review.

PMID:
12828668
7.

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.

Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group.

Haemophilia. 2011 Jan;17(1):2-10. doi: 10.1111/j.1365-2516.2010.02370.x. Epub 2010 Aug 22. Review.

PMID:
20731726
8.

Prophylactic factor replacement in hemophilia.

Carcao MD, Aledort L.

Blood Rev. 2004 Jun;18(2):101-13. Review.

PMID:
15010149
9.

Progress in the treatment of bleeding disorders.

Bergman GE.

Thromb Res. 2011 Jan;127 Suppl 1:S3-5. doi: 10.1016/j.thromres.2010.10.007. Epub 2010 Oct 29. Review.

PMID:
21035836
10.

Primary prophylaxis in children with haemophilia.

Coppola A, Di Capua M, De Simone C.

Blood Transfus. 2008 Sep;6 Suppl 2:s4-11. Review.

11.

Current issues in prophylactic therapy for persons with hemophilia.

Dunn AL, Abshire TC.

Acta Haematol. 2006;115(3-4):162-71. Review.

PMID:
16549891
12.

Prophylaxis in real life scenarios.

Fischer K, Konkle B, Broderick C, Kessler CM.

Haemophilia. 2014 May;20 Suppl 4:106-13. doi: 10.1111/hae.12425. Review.

PMID:
24762285
13.

Secondary prophylaxis in adolescent and adult haemophiliacs.

Tagliaferri A, Di Perna C, Rivolta GF.

Blood Transfus. 2008 Sep;6 Suppl 2:s17-20. Review.

14.

Prophylactic infusion regimens in the management of hemophilia.

Ljung RC.

Thromb Haemost. 1999 Aug;82(2):525-30. Review.

PMID:
10605746
15.

Management of joint bleeding in hemophilia.

Simpson ML, Valentino LA.

Expert Rev Hematol. 2012 Aug;5(4):459-68. Review.

PMID:
22992238
16.

The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.

Berntorp E.

Baillieres Clin Haematol. 1996 Jun;9(2):259-71. Review.

PMID:
8800504
17.

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.

Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O'Donnell J, Pasi KJ, Rangarajan S, Thomas A.

Haemophilia. 2016 Jul;22(4):487-98. doi: 10.1111/hae.13013. Epub 2016 Jun 16. Review.

PMID:
27311929
18.

Prophylaxis in children with hemophilia: is it the optimal treatment?

Lusher JM.

Thromb Haemost. 1997 Jul;78(1):726-9. Review. No abstract available.

PMID:
9198246
19.

Therapeutic properties and safety of recombinant factor VIII and factor IX.

Zdziarska J, Chojnowski K, Klukowska A, Łetowska M, Mital A, Podolak-Dawidziak M, Windyga J, Zawilska K; Working Group on Hemostasis of the Polish Society of Hematologists and Transfusiologists.

Pol Arch Med Wewn. 2009 Jun;119(6):403-9. Review.

20.

Treatment on demand--in vivo dose finding studies.

Escobar MA.

Haemophilia. 2003 Jul;9(4):360-7. Review.

PMID:
12828669

Supplemental Content

Support Center